Baxter International 10-Q 2022-06-30
Filed 2022-07-28. 7 sections, 197K characters. Original on sec.gov · Markdown · JSON
Cover and table of contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
_________________________________________________________________________________
FORM 10-Q
_________________________________________________________________________________
| ☒ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended June 30, 2022
| ☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from to
Commission file number 1-4448
_________________________________________________________________________________
BAXTER INTERNATIONAL INC.
(Exact name of registrant as specified in its charter)
_________________________________________________________________________________
| Delaware | 36-0781620 | |||||||||||||
| (State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) | |||||||||||||
| One Baxter Parkway, | Deerfield, | Illinois | 60015 | |||||||||||
| (Address of Principal Executive Offices) | (Zip Code) |
| 224. | 948.2000 | ||||||||||||||||
| (Registrant’s telephone number, including area code) |
_________________________________________________________________________________
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
| Common Stock, $1.00 par value | BAX (NYSE) | New York Stock Exchange | ||||||||||||
| Chicago Stock Exchange | ||||||||||||||
| 0.4% Global Notes due 2024 | BAX 24 | New York Stock Exchange | ||||||||||||
| 1.3% Global Notes due 2025 | BAX 25 | New York Stock Exchange | ||||||||||||
| 1.3% Global Notes due 2029 | BAX 29 | New York Stock Exchange |
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large accelerated filer | x | Accelerated filer | o | |||||||||||
| Non-accelerated filer | o | Smaller reporting company | ☐ | |||||||||||
| Emerging growth company | ☐ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No x
The number of shares of the registrant’s Common Stock, par value $1.00 per share, outstanding as of July 21, 2022 was 503,610,722 shares.
BAXTER INTERNATIONAL INC.
FORM 10-Q
For the quarterly period ended June 30, 2022
TABLE OF CONTENTS
PART I. FINANCIAL INFORMATION
Item 1. Financial Statements
Baxter International Inc.
Condensed Consolidated Balance Sheets (unaudited)
(in millions, except share information)
| June 30, 2022 | December 31, 2021 | |||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 1,852 | $ | 2,951 | ||||
| Accounts receivable, net of allowances of $125 in 2022 and $122 in 2021 | 2,473 | 2,629 | ||||||
| Inventories | 2,663 | 2,453 | ||||||
| Prepaid expenses and other current assets | 894 | 839 | ||||||
| Total current assets | 7,882 | 8,872 | ||||||
| Property, plant and equipment, net | 4,976 | 5,178 | ||||||
| Goodwill | 9,644 | 9,836 | ||||||
| Other intangible assets, net | 7,459 | 7,792 | ||||||
| Operating lease right-of-use assets | 566 | 630 | ||||||
| Other non-current assets | 1,304 | 1,213 | ||||||
| Total assets | $ | 31,831 | $ | 33,521 | ||||
| Current liabilities: | ||||||||
| Short-term debt | $ | 200 | $ | 301 | ||||
| Current maturities of long-term debt and finance lease obligations | 208 | 210 | ||||||
| Accounts payable | 1,282 | 1,246 | ||||||
| Accrued expenses and other current liabilities | 2,226 | 2,479 | ||||||
| Total current liabilities | 3,916 | 4,236 | ||||||
| Long-term debt and finance lease obligations, less current portion | 16,278 | 17,149 | ||||||
| Operating lease liabilities | 470 | 522 | ||||||
| Other non-current liabilities | 2,264 | 2,493 | ||||||
| Total liabilities | 22,928 | 24,400 | ||||||
| Commitments and contingencies | ||||||||
| Equity: | ||||||||
| Common stock, $1 par value, authorized 2,000,000,000 shares, issued 683,494,944 shares in 2022 and 2021 | 683 | 683 | ||||||
| Common stock in treasury, at cost,179,687,824 shares in 2022 and 181,879,516 shares in 2021 | (11,409) | (11,488) | ||||||
| Additional contributed capital | 6,253 | 6,197 | ||||||
| Retained earnings | 17,099 | 17,065 | ||||||
| Accumulated other comprehensive (loss) income | (3,767) | (3,380) | ||||||
| Total Baxter stockholders’ equity | 8,859 | 9,077 | ||||||
| Noncontrolling interests | 44 | 44 | ||||||
| Total equity | 8,903 | 9,121 | ||||||
| Total liabilities and equity | $ | 31,831 | $ | 33,521 |
The accompanying notes are an integral part of these condensed consolidated financial statements.
Baxter International Inc.
Condensed Consolidated Statements of Income (unaudited)
(in millions, except per share data)
| Three months ended June 30, | Six months ended June 30, | ||||||||||||||||
| 2022 | 2021 | 2022 | 2021 | ||||||||||||||
| Net sales | $ | 3,746 | $ | 3,098 | $ | 7,453 | $ | 6,044 | |||||||||
| Cost of sales | 2,293 | 1,865 | 4,652 | 3,666 | |||||||||||||
| Gross margin | 1,453 | 1,233 | 2,801 | 2,378 | |||||||||||||
| Selling, general and administrative expenses | 976 | 675 | 2,028 | 1,302 | |||||||||||||
| Research and development expenses | 148 | 139 | 298 | 267 | |||||||||||||
| Other operating income, net | (11) | (5) | (28) | (5) | |||||||||||||
| Operating income | 340 | 424 | 503 | 814 | |||||||||||||
| Interest expense, net | 89 | 34 | 174 | 68 | |||||||||||||
| Other (income) expense, net | (44) | (2) | (60) | 3 | |||||||||||||
| Income before income taxes | 295 | 392 | 389 | 743 | |||||||||||||
| Income tax expense | 40 | 91 | 61 | 142 | |||||||||||||
| Net income | 255 | 301 | 328 | 601 | |||||||||||||
| Net income attributable to noncontrolling interests | 3 | 3 | 5 | 5 | |||||||||||||
| Net income attributable to Baxter stockholders | $ | 252 | $ | 298 | $ | 323 | $ | 596 | |||||||||
| Earnings per share | |||||||||||||||||
| Basic | $ | 0.50 | $ | 0.59 | $ | 0.64 | $ | 1.18 | |||||||||
| Diluted | $ | 0.50 | $ | 0.59 | $ | 0.64 | $ | 1.17 | |||||||||
| Weighted-average number of shares outstanding | |||||||||||||||||
| Basic | 504 | 503 | 503 | 504 | |||||||||||||
| Diluted | 508 | 509 | 508 | 510 |
The accompanying notes are an integral part of these condensed consolidated financial statements.
Baxter International Inc.
Condensed Consolidated Statements of Comprehensive Income (Loss) (unaudited)
(in millions)
| Three months ended June 30, | Six months ended June 30, | ||||||||||||||||
| 2022 | 2021 | 2022 | 2021 | ||||||||||||||
| Net income | $ | 255 | $ | 301 | $ | 328 | $ | 601 | |||||||||
| Other comprehensive income (loss), net of tax: | |||||||||||||||||
| Currency translation adjustments, net of tax expense (benefit) of $2 and $(4) for the three months ended June 30, 2022 and 2021, respectively, and ($9) and $13 for the six months ended June 30, 2022 and 2021, respectively. | (417) | 88 | (432) | (120) | |||||||||||||
| Pension and other postretirement benefits, net of tax expense of $5 and $3 for the three months ended June 30, 2022 and 2021, respectively, and $8 and $11 for the six months ended June 30, 2022 and 2021, respectively. | 23 | 11 | 32 | 41 | |||||||||||||
| Hedging activities, net of tax expense of $4 and $2 for the three months ended June 30, 2022 and 2021, respectively, and $3 and $5 for the six months ended June 30, 2022 and 2021, respectively. | 13 | 5 | 11 | 17 | |||||||||||||
| Available-for-sale debt securities, net of tax expense of zero for the three months ended June 30, 2022 and 2021, respectively, and $1 and zero for the six months ended June 30, 2022 and 2021, respectively. | 1 | — | 2 | — | |||||||||||||
| Total other comprehensive income (loss), net of tax | (380) | 104 | (387) | (62) | |||||||||||||
| Comprehensive income (loss) | (125) | 405 | (59) | 539 | |||||||||||||
| Less: Comprehensive income attributable to noncontrolling interests | 3 | 3 | 5 | 5 | |||||||||||||
| Comprehensive income (loss) attributable to Baxter stockholders | $ | (128) | $ | 402 | $ | (64) | $ | 534 |
The accompanying notes are an integral part of these condensed consolidated financial statements.
Baxter International Inc.
Condensed Consolidated Statements of Changes in Equity (unaudited)
(in millions)
| For the three months ended June 30, 2022 | ||||||||||||||||||||||||||||||||
| Baxter International Inc. stockh |
Showing the first 8K of 112K characters. Open the full section
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
Refer to our Annual Report on Form 10-K for the year ended December 31, 2021 for management’s discussion and analysis of our financial condition and results of operations. The following is management’s discussion and analysis of our financial condition and results of operations for the three and six months ended June 30, 2022 and 2021.
RESULTS OF OPERATIONS
Net income attributable to Baxter stockholders for the three and six months ended June 30, 2022 totaled $252 million, or $0.50 per diluted share, and $323 million, or $0.64 per diluted share, compared to $298 million, or $0.59 per diluted share, and $596 million, or $1.17 per diluted share, for the three and six months ended June 30, 2021. The first quarter of 2022 was the first full quarter reflecting Hillrom results of operations after the December 13, 2021 acquisition. Net income for the three and six months ended June 30, 2022 included special items which decreased net income by $191 million and $591 million, respectively, or $0.37 and $1.16 per diluted share, respectively, as further discussed below. Net income for the three and six months ended June 30, 2021 included special items which decreased net income by $111 million and $199 million, respectively, or $0.21 and $0.39 per diluted share, respectively, as further discussed below.
Special Items
The following table provides a summary of our special items and the related impact by line item on our results for the three and six months ended June 30, 2022 and 2021.
| Three months ended June 30, | Six months ended June 30, | ||||||||||||||||
| (in millions) | 2022 | 2021 | 2022 | 2021 | |||||||||||||
| Gross Margin | |||||||||||||||||
| Intangible asset amortization expense | $ | (112) | $ | (67) | $ | (234) | $ | (131) | |||||||||
| Business optimization items1 | (6) | (10) | (8) | (31) | |||||||||||||
| Acquisition and integration expenses2 | (9) | — | (173) | — | |||||||||||||
| European medical devices regulation3 | (12) | (11) | (23) | (19) | |||||||||||||
| Product-related items5 | — | — | (23) | — | |||||||||||||
| Total Special Items | $ | (139) | $ | (88) | $ | (461) | $ | (181) | |||||||||
| Impact on Gross Margin Ratio | (3.7 pts) | (2.8 pts) | (6.2 pts) | (3.0 pts) | |||||||||||||
| Selling, General and Administrative (SG&A) Expenses | |||||||||||||||||
| Intangible asset amortization expense | $ | 81 | $ | — | $ | 176 | $ | — | |||||||||
| Business optimization items1 | 36 | 8 | 114 | 14 | |||||||||||||
| Acquisition and integration expenses2 | 20 | 1 | 44 | 2 | |||||||||||||
| Investigation and related costs4 | — | 17 | — | 28 | |||||||||||||
| Total Special Items | $ | 137 | $ | 26 | $ | 334 | $ | 44 | |||||||||
| Impact on SG&A Ratio | 3.7 pts | 0.9 pts | 4.5 pts | 0.7 pts | |||||||||||||
| Research and Development (R&D) Expenses | |||||||||||||||||
| Business optimization items1 | $ | — | $ | — | $ | 1 | $ | — | |||||||||
| Total Special Items | $ | — | $ | — | $ | 1 | $ | — | |||||||||
| Impact on R&D Ratio | 0.0 pts | 0.0 pts | 0.0 pts | 0.0 pts | |||||||||||||
| Other Operating Income, net | |||||||||||||||||
| Acquisition and integration expenses2 | $ | (11) | $ | (5) | $ | (28) | $ | (5) | |||||||||
| Total Special Items | $ | (11) | $ | (5) | $ | (28) | $ | (5) | |||||||||
| Other Income (Expense), net | |||||||||||||||||
| Pension curtailment6 | $ | (11) | $ | — | $ | (11) | $ | — | |||||||||
| Total Special Items | $ | (11) | $ | — | $ | (11) | $ | — | |||||||||
| Income Tax Expense | |||||||||||||||||
| Tax matters7 | $ | — | $ | 22 | $ | — | $ | 22 | |||||||||
| Tax effects of special items8 | (63) | (20) | (166) | (43) | |||||||||||||
| Total Special Items | $ | (63) | $ | 2 | $ | (166) | $ | (21) | |||||||||
| Impact on Effective Tax Rate | (5.2 pts) | 5.2 pts | (4.1 pts) | 2.1 pts |
Intangible asset amortization expense, which increased significantly from the prior year due to the Hillrom acquisition, is identified as a special item to facilitate an evaluation of current and past operating performance and is consistent with how management and our Board of Directors assess performance. Additional special items are identified above because they are highly variable, difficult to predict and of a size that may substantially impact our reported results of operations for the period. Management believes that providing the separate impact of those items may provide a more complete understanding and facilitate a fuller analysis of our results of operations, particularly in evaluating performance from one period to another.
1In 2022 and 2021, our results were impacted by costs associated with our execution of programs to optimize our organization and cost structure. These actions included streamlining our international operations, rationalizing our manufacturing and distribution facilities, reducing our general and administrative infrastructure, re-aligning certain R&D activities and cancelling certain R&D programs. In the current period, restructuring charges include actions taken in connection with our integration of Hillrom, which we acquired in
December 2021. Our results in 2022 included business optimization charges of $42 million in the second quarter and $123 million in the first half. Our results in 2021 included business optimization charges of $18 million in the second quarter and $45 million in the first half. Refer to Note 10 in Item 1 of this Quarterly Report on Form 10-Q for further information regarding these charges and related liabilities.
2Our results in 2022 included $18 million in the second quarter and $189 million in the first half of acquisition and integration-related expenses. Those costs included $29 million in the second quarter and $217 million in the first half related to our acquisition of Hillrom, primarily reflecting $159 million of incremental costs of sales in the first half from the fair value step-ups on acquired Hillrom inventory that was sold in the first quarter. We have not incurred and we do not expect to incur significant incremental cost of sales from those inventory fair value step-ups beyond what was recognized in the first quarter 2022. Other integration expenses in the current period included third party consulting costs related to our integration
Showing the first 8K of 66K characters. Open the full section
Item 3. Quantitative and Qualitative Disclosures About Market Risk
Currency Risk
We are primarily exposed to foreign exchange risk with respect to revenues generated outside of the United States denominated in the Euro, British Pound, Chinese Renminbi, Korean Won, Australian Dollar, Canadian Dollar, Japanese Yen, Colombian Peso, Brazilian Real, Mexican Peso, Indian Rupee and Swedish Krona. We manage our foreign currency exposures on a consolidated basis, which allows us to net exposures and take advantage of any natural offsets. In addition, we use derivative and nonderivative financial instruments to further reduce the net exposure to foreign exchange. Gains and losses on the hedging instruments offset losses and gains on the hedged transactions and reduce the earnings and stockholders’ equity volatility relating to foreign exchange. However, we don't hedge our entire foreign exchange exposure and are still subject to earnings and stockholders' equity volatility relating to foreign exchange risk. Financial market and currency volatility may limit our ability to cost-effectively hedge these exposures.
We use options and forwards to hedge the foreign exchange risk to earnings relating to forecasted transactions and recognized assets and liabilities denominated in foreign currencies. The maximum term over which we have cash flow hedge contracts in place related to foreign exchange risk on forecasted transactions as of June 30, 2022 is 12 months. We also enter into derivative instruments to hedge foreign exchange risk on certain intra-company and third-party receivables and payables and debt denominated in foreign currencies.
As part of our risk-management program, we perform sensitivity analyses to assess potential changes in the fair value of our foreign exchange instruments relating to hypothetical and reasonably possible near-term movements in foreign exchange rates.
A sensitivity analysis of changes in the fair value of foreign exchange contracts outstanding as of June 30, 2022, while not predictive in nature, indicated that if the U.S. Dollar uniformly weakened by 10% against all currencies, the net pre-tax asset balance of $5 million with respect to those contracts would change by $57 million.
The sensitivity analysis model recalculates the fair value of the foreign exchange contracts outstanding as of June 30, 2022 by replacing the actual exchange rates as of June 30, 2022 with exchange rates that are 10% weaker compared to the actual exchange rates for each applicable currency. All other factors are held constant. These sensitivity analyses disregard the possibility that currency exchange rates can move in opposite directions and that gains from one currency may or may not be offset by losses from another currency. The analyses also disregard the offsetting change in value of the underlying hedged transactions and balances.
In February 2022, the three-year cumulative inflation rate in Turkey exceeded 100 percent. As a result, on April 1, 2022, we began reporting the results of our subsidiary in that jurisdiction using highly inflationary accounting, which requires that the functional currency of the entity be changed to the reporting currency of its parent. As of June 30, 2022, our subsidiary in Turkey had net monetary assets of $40 million.
Our subsidiary in Argentina is reported using highly inflationary accounting effective July 1, 2018. Changes in the value of the Argentine Peso applied to our peso-denominated net monetary asset positions are recorded in income at the time of the change. As of June 30, 2022, our net monetary assets denominated in Argentine Pesos are not significant.
Interest Rate and Other Risks
Refer to the caption “Interest Rate and Other Risks” in the “Financial Instrument Market Risk” section of the 2021 Annual Report. There were no significant changes during the quarter ended June 30, 2022.
Item 4. Controls and Procedures
Evaluation of Disclosure Controls and Procedures
Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the Exchange Act)) as of June 30, 2022. Based on that evaluation, our Chief Executive Officer and our Chief Financial Officer concluded that our disclosure controls and procedures were effective as of June 30, 2022.
Changes in Internal Control over Financial Reporting
There have been no changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended June 30, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
PART II. OTHER INFORMATION
Item 1. Legal Proceedings
The information in Part I, Item 1, Note 6 is incorporated herein by reference.
Item 1A. Risk Factors
We do not believe that there have been any material changes to the risk factors previously disclosed in our 2021 Annual Report.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
| Period | Total number of shares purchased (1) | Average price paid per share | Total number of shares purchased as part of publicly announced program(1) | Approximate dollar value of shares that may yet be purchased under the program(1) | ||||||||||
| April 1, 2022 through April 30, 2022 | — | $ | — | — | ||||||||||
| May 1, 2022 through May 31, 2022 | — | $ | — | — | ||||||||||
| June 1, 2022 through June 30, 2022 | 125,000 | $ | 64.91 | 125,000 | ||||||||||
| Total | 125,000 | $ | 64.91 | 125,000 | $ | 1,289,019,296 |
(1) In July 2012, we announced that our Board of Directors authorized us to repurchase up to $2.0 billion of our common stock on the open market or in private transactions. The Board of Directors increased this authority by an additional $1.5 billion in each of November 2016 and February 2018, by an additional $2.0 billion in November 2018 and by an additional $1.5 billion in October 2020. During the second quarter of 2022, we repurchased approximately 0.1 million shares for $8 million pursuant to this authority through a Rule 10b5-1 purchase plan. We had $1.3 billion remaining under this program as of June 30, 2022. This program does not have an expiration date.
Item 6. Exhibits
Exhibit Index:
- Filed herewith.
Signature
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| BAXTER INTERNATIONAL INC. | ||||||||
| (Registrant) | ||||||||
| Date: July 28, 2022 | ||||||||
| By: | /s/ James K. Saccaro | |||||||
| James K. Saccaro Executive Vice President and Chief Financial Officer (duly authorized officer and principal financial officer) |